Genomic characterization of
Carbapenemase
Citrobacter freundii
OXA-48
VIM-1
Whole genome sequencing
Journal
Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411
Informations de publication
Date de publication:
2019
2019
Historique:
received:
05
07
2019
accepted:
16
10
2019
entrez:
6
11
2019
pubmed:
7
11
2019
medline:
8
7
2020
Statut:
epublish
Résumé
The emergence of carbapenemase-producing (CP) Twelve fecal samples, collected between 2013 and 2015 from 9 patients with AL, were screened for the presence of CP strains by selecting them on MacConkey agar supplemented with ertapenem (0.5 mg/L). Bacteria were identified by MALDI-TOF mass spectrometry and were phenotypically characterized. Whole genome sequencing of Three carbapenem-resistant We report in our study, the intestinal carrying of
Sections du résumé
Background
The emergence of carbapenemase-producing (CP)
Materials and methods
Twelve fecal samples, collected between 2013 and 2015 from 9 patients with AL, were screened for the presence of CP strains by selecting them on MacConkey agar supplemented with ertapenem (0.5 mg/L). Bacteria were identified by MALDI-TOF mass spectrometry and were phenotypically characterized. Whole genome sequencing of
Results
Three carbapenem-resistant
Conclusion
We report in our study, the intestinal carrying of
Identifiants
pubmed: 31687131
doi: 10.1186/s13756-019-0630-3
pii: 630
pmc: PMC6820958
doi:
Substances chimiques
Bacterial Proteins
0
beta-Lactamases
EC 3.5.2.6
carbapenemase
EC 3.5.2.6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
167Informations de copyright
© The Author(s). 2019.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Expert Rev Mol Diagn. 2019 Apr;19(4):349-362
pubmed: 30895843
Br J Clin Pharmacol. 2015 Feb;79(2):195-207
pubmed: 24341410
Antimicrob Agents Chemother. 2014;58(1):212-20
pubmed: 24145532
BMC Infect Dis. 2016 Oct 22;16(1):595
pubmed: 27770796
J Infect Chemother. 2019 Aug;25(8):605-609
pubmed: 31023570
Am J Hematol. 2016 Nov;91(11):1076-1081
pubmed: 27428072
Infect Genet Evol. 2016 Sep;43:74-82
pubmed: 27174090
Leuk Lymphoma. 2016 Oct;57(10):2245-58
pubmed: 27339405
Diagn Microbiol Infect Dis. 2017 Mar;87(3):295-297
pubmed: 27993422
Antimicrob Agents Chemother. 2010 Jan;54(1):320-7
pubmed: 19901094
Microb Drug Resist. 2019 Jan/Feb;25(1):63-71
pubmed: 30129868
J Antimicrob Chemother. 2015 Nov;70(11):3146-53
pubmed: 26209312
J Antimicrob Chemother. 2014 Jul;69(7):1792-5
pubmed: 24583362
New Microbes New Infect. 2015 Jul 10;7:89-93
pubmed: 26442150
Br J Haematol. 2016 Feb;172(4):497-511
pubmed: 26492511
J Antimicrob Chemother. 2017 Dec 1;72(12):3283-3287
pubmed: 29029114
J Comput Biol. 2012 May;19(5):455-77
pubmed: 22506599
Mediterr J Hematol Infect Dis. 2017 Jan 01;9(1):e2017002
pubmed: 28101308
Future Microbiol. 2016;11(3):455-66
pubmed: 26974504
Bioinformatics. 2016 Mar 15;32(6):929-31
pubmed: 26576653
Microb Drug Resist. 2017 Apr;23(3):335-344
pubmed: 27314660
J Antimicrob Chemother. 2015 Nov;70(11):2987-91
pubmed: 26260129
Euro Surveill. 2016 Sep 15;21(37):
pubmed: 27685838
Microb Drug Resist. 2018 Apr;24(3):337-345
pubmed: 28799835
Infect Drug Resist. 2018 Sep 12;11:1447-1460
pubmed: 30254476
Sci Rep. 2018 Jul 13;8(1):10653
pubmed: 30006537
Mediterr J Hematol Infect Dis. 2018 May 01;10(1):e2018025
pubmed: 29755703
Bioinformatics. 2014 Jul 15;30(14):2068-9
pubmed: 24642063